PharmAsia Summit Keynote Panel Includes China Pharma Leaders From Merck & Co., Inc., Pfizer Inc. and Sanofi (France)

July 19, 2012 |

3 min read

SHANGHAI, CHINA--(Marketwire - July 18, 2012) - Elsevier Business Intelligence and The BayHelix Group announced today a keynote panel of China pharma leaders from Merck, Pfizer and Sanofi who will discuss the changing commercial landscape in China and how pharma companies must develop new business models to compete and win in the market.

The keynote panel will feature Dr. Wu Xiaobing, country manager, Pfizer; Mr. Michel Vounatsos, Chairman and President, Merck/MSD; and Mr. Fabrice Baschiera, General Manager Pharmaceutical Operations, Sanofi.

“As China transitions from a hospital-based system to a primary-care system, companies will need to find new commercial models to succeed in the world’s second largest pharma market,” said Joshua Berlin, executive editor, PharmAsia News, and a member of the organizing committee. “This keynote panel will provide attendees with a rare opportunity to hear from three of the top commercial minds in China.”

The PharmAsia Summit (http://www.PharmAsiaSummit.com), to be held Sept. 24-26 in Shanghai, is sponsored by Elsevier Business Intelligence and The BayHelix Group. The Summit will feature data and case studies from China, India and other emerging markets focusing on two key imperatives of innovation: (1) Getting Better Products To Market Faster; and (2) Creating Value For Patients And Payers.

To kick off the Summit, Elsevier, BayHelix and the Monitor Group will release an exclusive report exploring how China could disrupt the innovation paradigm, based on an industry survey and discussions with key corporate leaders and policy makers.

“At the PharmAsia Summit, attendees will also have the chance to hear from leading Chinese domestic companies that are transitioning to innovation,” said Jimmy Zhang, chairman of BayHelix, and a member of the organizing committee. “Companies like Beta Pharma, Hengrui and Fosun will provide unique insights into how innovation is developing on the ground in China.”

The program for this year’s Summit has been created by an organizing committee chaired by Steve Yang, VP, Head of R&D for Asia & Emerging Markets, AstraZeneca PLC.

For further information, please visit: http://www.PharmAsiaSummit.com. To participate in the industry survey (which includes a 15% discount to attend the PharmAsia Summit-Shanghai), please visit: http://bit.ly/I109bx.

About Elsevier Business Intelligence:

Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and “The Pink Sheet.” For more information, visit: http://www.ElsevierBi.com.

About BayHelix Group:

BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. For more information, visit: http://www.bayhelix.org.